Effect of NAT2 gene polymorphisms on cholesterol metabolism in patients with arterial hypertension

Acetylation is a key in turning atsetilkoenzim A to acetoacetyl-CoA and is required for the synthesis of holesterol. The process of acetylation is carried out mainly by the enzyme N-acetyltransferase 2 and may be dependent on the allelic variants of the gene NAT2. Lipid composition of blood have been found in 40–85% of hypertensive patients and are one of the most adverse prognostic signs. Presents the data on the distribution of allelic variants of NAT2 gene among patients with different stages of arterial hypertension, as well as depending on the cholesterol level of mutations in this gene. Among patients with I degree of hypertension was significantly (p < 0,05) more often homozygous for the «slow» allelic variants. The study shows that patients, who are «slow» acetylators, have significantly lower levels of blood cholesterol. «Slow» allelic variants of NAT2 gene contribute to reducing the enzyme N-acetyltransferase, slowing the conversion of the reaction acetyl-CoA to acetoacetyl-CoA and breaking multistep synthesis of a chain of cholesterol. Mutation of the gene encoding the enzyme N-acetyltransferase, suffers the synthesis of cholesterol, which can significantly reduce the risk of cardiovascular events in hypertensive patients.